ReviewFrontiers in pharmacology2025
Overcoming the blood-brain barrier: targeted delivery strategies for gliomas.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical registry metadata as a hidden bottleneck in AI-driven drug discovery: a computational audit of translational phase data in glioma research.Scientific reports · 2026Article
- Mapping the landscape and evolution of drug delivery for glioma: a bibliometric and visual analysis.Discover oncology · 2026Article
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological gliomas, as the most common and deadly primary brain tumors, face two major therapeutic obstacles: the blockade of the blood-brain barrier (BBB) and high tumor heterogeneity. In recent years, research on novel drug delivery systems has brought hope for glioma treatment. This article elaborates on the research progress of novel drug delivery systems in glioma treatment, including various nanocarriers, targeted delivery strategies, and gene therapy drug delivery systems. It analyzes their advantages and challenges, outlooks future development directions, and aims to provide a reference for optimizing drug delivery systems for glioma therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.